China Pharma Holdings Prices $5 Million Direct Offering

The company intends to allocate the net proceeds toward general corporate purposes and working capital requirements. FT Global Capital, Inc. is serving as the exclusive placement agent for the transaction, which was executed under a shelf registration statement previously declared effective by the U.S. Securities and Exchange Commission.

China Pharma Holdings operates as a specialty pharmaceutical firm focusing on high-incidence medical conditions, including cardiovascular, infectious, and digestive diseases. The company maintains an integrated business model supported by eight GMP-certified production lines and a nationwide distribution network in China.